Table 2.

Refined prognostic metagenes and internally cross-validated performances

5-years DMFS (%)
SubtypeDatacollectionNo. of pointsMetageneNumberof genesGenesLow riskIntermediate riskHigh riskP
ERHER2PROGNOSTIC179Immune25CXCL13, PLEK, IFNG, SLAMF7, IL2RB, PRF1, IRF1, PTPN22, IKZF1, APOBEC3G, IL2RA, ITGAL, CXCL9, GZMA, GZMB, HLA-E, CCR5, CD8A, SIRPG, CST7, GNLY, CECR1, PNOC, LCP1, HLA-DMB77.7975.2757.920.0089
HER2+PROGNOSTIC122Immune10HLA-E, GIMAP5, IRF1, CXCL13, SEL1L3, GZMB, IKZF1, PRF1, FGL2, BIN286.5681.3451.269.55E-05
ER+HER2PROGNOSTIC508Proliferation10NCAPG, BUB1B, PRC1, CCNB2, RAD51AP1, ORC6, FANCI, UBE2C, AURKA, KIF20A91.4788.3463.615.25E-14
ER+HER2 (intermediate/high proliferation)aTAM394ER-related10ABAT, CA12, MCCC2, SCUBE2, LRIG1, FAM63A, CCDC176, MYB, CACNA1D, GATA393.9985.1175.249.12E-06

NOTE: Gene selected in both ERHER2 and HER2+ cases are in bold.

  • aOnly intermediate and high tertiles by proliferation metagene were included in this analysis.